首页> 外文期刊>Romanian Journal of Morphology and Embryology >The study of p53 and CA19-9 prognostic molecular markers in colorectal carcinomas
【24h】

The study of p53 and CA19-9 prognostic molecular markers in colorectal carcinomas

机译:大肠癌中p53和CA19-9预后分子标志物的研究

获取原文
       

摘要

Immunohistochemistry represents a relatively new identification technique of cellular and tissular antigens due to an antigen-antibody binding interactions, applied more and more in the pathology laboratories for positive and differential diagnosis of premalignant and malignant lesions and also for evolutive prognosis of tumoral formations. Immunohistochemistry coloration is based on the antigen-antibody affinity, the antibody binding situs being identified either by antibody coloration direct methods or by using an indirect method where the marking is supplied by antibodies called secondary or even tertiary. The present study is based on the immunohistochemical investigation of some molecular markers with a prognosis value in colorectal cancers (CCR), like the antibody p53 immune expression and of some factors supposed to have prognosis value, such as CA19-9 (carcinoembryonic antigen, carbohydrate antigen or Lewis antigen). In the last decade, the studies have tried to define the prognosis of the molecular markers that allow the identification of the patients with recurrent risk after surgical treatment and who can benefit from chemotherapy in an efficient way. The purpose of the study on immunohistochemical markers is to aim towards the treatment based on molecular phenotypes of colorectal tumors. In 2000, according to the Consensus Conference of the Colorectal Working Group of the American Joint Committee on Cancer Prognostic Factors (AJC), there were established four categories of prognosis factors in colorectal cancers based on the practical importance and the number of studies referring to them. The present study is centered on the prognosis factors from the second B category (p53 oncoprotein expression) and the fourth category (CA19-9 immunomarker expression).
机译:免疫组织化学代表了一种相对新的鉴定细胞和组织抗原的技术,这是由于抗原-抗体的结合相互作用,越来越多地应用于病理学实验室以对恶性前和恶性病变进行阳性和鉴别诊断,以及对肿瘤形成的发展性预测。免疫组织化学着色是基于抗原-抗体亲和力,通过抗体着色直接方法或通过间接方法(其中标记由称为第二抗体或什至第三抗体的抗体提供)来鉴定抗体结合位点。本研究基于对大肠癌(CCR)具有预后价值的某些分子标志物的免疫组织化学研究,例如抗体p53的免疫表达以及一些具有预后价值的因素,例如CA19-9(癌胚抗原,碳水化合物抗原或路易斯抗原)。在过去的十年中,研究试图确定分子标记物的预后,以鉴定出手术治疗后有复发风险并且可以从化学疗法中受益的患者。免疫组织化学标记物研究的目的是基于大肠肿瘤的分子表型进行治疗。根据美国癌症预后因素联合委员会(AJC)大肠癌工作组共识会议,在2000年,根据实际重要性和参考研究的数量,建立了四类大肠癌预后因素。 。本研究集中于第二类B类(p53癌蛋白表达)和第四类(CA19-9免疫标志物表达)的预后因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号